Gian Luca De Salvo

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

Giuseppe Lombardi, Gian Luca De Salvo, Alba A. Brandes et al. · The Lancet Oncology · 2018 · 367 citations

Neuro-oncology, Medicine, Relapsed Glioblastoma +10

A Randomized Clinical Trial on Sentinel Lymph Node Biopsy Versus Axillary Lymph Node Dissection in Breast Cancer

G. Zavagno, Gian Luca De Salvo, Giuliano Scalco et al. · Annals of Surgery · 2008 · 310 citations

Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution’s Experience with 52 Patients

L Campana, Simone Mocellin, Michela Basso et al. · Annals of Surgical Oncology · 2008 · 288 citations

Single Institution ’, Bleomycin-based Electrochemotherapy, Surgery +4

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

Gianni Bisogno, Gian Luca De Salvo, Christophe Bergeron et al. · The Lancet Oncology · 2019 · 231 citations · Full text

Oncology, Metronomic Therapy, Rms 2005 +9

Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: Results of the sentinella–GIVOM Italian randomised clinical trial

Paola Del Bianco, G. Zavagno, Paolo Burelli et al. · European Journal of Surgical Oncology · 2007 · 212 citations

Surgical Oncology, Sentinella–givom Italian, Breast Oncology +9